UPDATE 1-Gilead hepatitis C drug sales fall, but profit beats estimates

UPDATE 1-Gilead hepatitis C drug sales fall, but profit beats estimates


Third quarter sales of Gilead Sciences Inc's flagship hepatitis C drugs fell by more than half as competition increased, sending net profit down 22 percent from a year earlier, the U.S. biotechnology company reported on Thursday. But the results beat analyst estimates and Gilead slightly raised its full-year outlook for product sales to between $20.8 billion and $21.3 billion from a previous range of $20 billion to $21 billion.



from Biotech News
Share:

Комментариев нет:

Отправить комментарий

Pharmacy News Digest

Архив блога